The U.S. Food and Drug Administration has approved a first-of-its-kind medication for adults whose high blood pressure remains dangerously high despite taking multiple existing drugs. The new treatment, Baxfendy (baxdrostat), works by blocking a hormone that drives blood pressure upward, offering a fresh option for millions of patients who have seen little therapeutic progress in two decades.
Hypertension affects an estimated 1.4 billion people worldwide. In the United States, about half of patients taking two or more blood pressure medications still have persistently elevated readings. Uncontrolled hypertension is a leading risk factor for heart attack, stroke, kidney damage and dementia. Baxfendy is the first approved aldosterone synthase inhibitor, a class of drug that specifically reduces production of aldosterone, a hormone that raises blood pressure by promoting sodium and water retention. By targeting this root cause, the medication aims to help patients whose blood pressure has not responded to standard treatments.
The approval was based on the BaxHTN Phase III trial, which enrolled 796 patients with uncontrolled or resistant hypertension who were already on two or more medications. At 12 weeks, patients taking the 2 mg dose of Baxfendy saw an average reduction in seated systolic blood pressure of 15.7 mmHg, compared with 5.8 mmHg for placebo. The placebo-adjusted drop was 9.8 mmHg for the 2 mg dose and 8.7 mmHg for the 1 mg dose, both statistically significant. Epidemiological data suggest that lowering systolic blood pressure by 10 mmHg can reduce the risk of major cardiovascular events by roughly 20 percent. The drug was generally well tolerated with no unexpected safety findings.
For patients and clinicians, this innovation arrives at a critical time. An estimated 23 million adults in the United States remain uncontrolled despite taking two or more antihypertensive medicines. The new therapy offers a mechanism that has not been available before, targeting the aldosterone pathway that plays a key role in stubborn hypertension. Researchers noted that elevated aldosterone levels are strongly linked to poor blood pressure control and progression of heart and kidney disease.
Looking ahead, Baxfendy is being studied in additional clinical trials for other conditions where aldosterone plays a harmful role. For the millions of people who struggle to control their blood pressure despite lifestyle changes and existing medications, this new class of treatment brings a long awaited and hopeful step forward.